Recommended Topic Related To:

Cystadane

"The U.S. Food and Drug Administration today announced the approval of Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are less than 8 years of age. In addition, the Risk Evaluatio"...

Cystadane

PATIENT INFORMATION

Patients should be advised of the following information before beginning treatment with Cystadane (betaine anhydrous) :

Dosing and Administration

  • Instruct patients and caregivers that Cystadane (betaine anhydrous) should only be taken as directed by their healthcare professional.
  • Instruct patients and caregivers to administer Cystadane (betaine anhydrous) as follows:
    • Shake bottle lightly before removing cap.
    • Measure with the scoop provided.
    • Measure the number of scoops as prescribed by their healthcare professional. One level scoop (1.7 mL) is equivalent to 1 gram of betaine anhydrous powder.
    • Mix powder with 4 to 6 ounces (120 to 180 mL) of water, juice, milk, or formula until completely dissolved, or mix with food, then ingest mixture immediately.
    • Always replace the cap tightly after using, and protect powder from moisture.

Last reviewed on RxList: 4/22/2010
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD